Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $8.14

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $8.1429.

A number of analysts recently weighed in on HUMA shares. BTIG Research reissued a “buy” rating and issued a $6.00 price objective on shares of Humacyte in a research report on Monday, February 9th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Humacyte in a research note on Monday, December 1st. UBS Group reiterated a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Finally, Benchmark dropped their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 21st.

Humacyte Price Performance

Humacyte stock opened at $1.12 on Friday. Humacyte has a 12-month low of $0.88 and a 12-month high of $3.36. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. The firm has a 50-day moving average price of $1.09 and a 200-day moving average price of $1.32. The firm has a market capitalization of $209.74 million, a PE ratio of -4.87 and a beta of 1.89.

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in the business. R Squared Ltd purchased a new stake in shares of Humacyte during the fourth quarter valued at $25,000. Atom Investors LP purchased a new position in Humacyte in the 4th quarter worth about $25,000. Truist Financial Corp bought a new stake in Humacyte during the 3rd quarter valued at about $28,000. Prudential Financial Inc. bought a new stake in Humacyte during the 2nd quarter valued at about $28,000. Finally, Financial Advisors Network Inc. purchased a new stake in Humacyte in the 2nd quarter valued at about $28,000. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.